By Sheeba M. | April 19, 2026
Green Thumb Industries vs. Cresco Labs: Mid-Tier MSO Showdown After Q1 2026 Earnings Season
The mid-tier MSO cohort has been punching above its weight class in 2026, and two names stand out in the post-earnings haze: Green Thumb Industries (GTBIF) and Cresco Labs (CRLBF). Both reported Q1 2026 numbers in the last two weeks, and both beat consensus estimates. But the quality of the beats — and what they imply for the rest of the year — tells very different stories.
Green Thumb Industries: The Retail Play
GTBIF posted Q1 revenue of $278 million, up 18% year-over-year, with adjusted EBITDA of $52 million — a 19% margin that’s actually the highest among mid-tier MSOs this quarter. The RISE Dispensaries brand continues to be GTBIF’s crown jewel. Same-store sales grew 11% sequentially, and the company’s loyalty program now has 1.4 million active members, up from 900,000 a year ago.
What’s telling is where Green Thumb is investing: new store openings in Illinois, New Jersey, and Florida — all high-costhigh-revenue adult-use or medical markets. The company guided to 15-18 new store openings in 2026, which would bring total retail locations to roughly 100 by year-end.
The bull case for GTBIF is straightforward — more dispensaries means more proprietary product sales, and proprietary product has better margins than white-labelSKU-push. Green Thumb’s house of brands (including the popular Rythm flower line and OOGE concentrates) is getting stronger shelf presence in its own stores.
Cresco Labs: Wholesale at Scale
Cresco Labs took a different approach. Revenue came in at $241 million for Q1 2026, up 14% YoY, with adjusted EBITDA of $38 million. The beat came from volume — Cresco moved more product through wholesale channels than any prior quarter, particularly in California and Ohio.
But here’s the concern: Cresco’s wholesale-heavy model means it’s exposed to price compression in mature markets like Colorado and Oregon in a way that retail-heavy operators aren’t. When flower prices fall, wholesale sell-through suffers. Cresco has been compensating by pushing into branded wholesale deals with third-party retailers, but that means less pricing power and lower take rates.
The Divergence and the Bet
Both companies are profitable. Both are growing. But the strategic choices are creating a fork in the road.
GTBIF is building a consumer brand franchise — the kind of loyal customer base that survives price wars and market downturns. Its loyalty data (1.4M members, repeat purchase rates, basket sizing) is a genuine moat that takes years to build.
CRLBF is chasing volume and scale, which works in an expanding market but gets squeezed when markets plateau. Its acquisition of Sprout Health Group in Q4 2025 was an interesting vertical move, but the integration is still ongoing and may drag margins in Q2-Q3 2026.
Verdict
If you had to pick one mid-tier MSO to hold through 2026, GTBIF is the cleaner story. Better margins, stronger brand, clear retail expansion roadmap, and the loyalty flywheel gives it pricing power that Cresco’s wholesale model simply doesn’t have.
That said, CRLBF isn’t cheap for a reason — if Ohio’s adult-use rollout delivers above-consensus sales, the wholesale lever could push CRLBF’s Q3-Q4 numbers higher. It’s a higher-beta, higher-potential-execution story.
Watch both heading into the summer conference season and the SAFE Banking Act vote — either could be a near-term catalyst.
Sources
- Green Thumb Industries IR — Q1 2026 earnings release
- Cresco Labs IR — Q1 2026 earnings release
- Bloomberg Intelligence — MSO sector valuation models
- SEC EDGAR — GTBIF and CRLBF 10-Q filings
Track cannabis stocks with the Weedstock Real-Time Tracker